CTOs on the Move

Ash Stevens Inc

www.ashstevens.com

 
Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asterias Biotherapeutics

Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.

QUATRx Pharmaceuticals Company

QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Personalis

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.

Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.